Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | BibSonomy

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
, , , , , , , , и .
J.Clin.Oncol. 26 (32): 5204-5212 (2008)

PURPOSE: Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported in approximately 10% of the patients. Detailed cardiovascular monitoring during TKI treatment may reveal early signs of myocardial damage. PATIENTS AND METHODS: In this observational, single-center study, all patients intended for TKI treatment were analyzed for coronary artery disease (CAD) risk factors, history or evidence of CAD, hypertension, rhythm disturbances, and heart failure. Monitoring included assessment of symptoms, ECGs, and biochemical markers (ie, creatine kinase-MB, troponin T). Echocardiography was performed at baseline in selected patients and in all patients who experienced a cardiac event. A cardiac event was defined as the occurrence of increased enzymes if normal at baseline, symptomatic arrhythmia that required treatment, new left ventricular dysfunction, or acute coronary syndrome.
  • @kanefendt
К этой публикации ещё не было создано рецензий.

распределение оценок
средняя оценка пользователей0,0 из 5.0 на основе 0 рецензий
    Пожалуйста, войдите в систему, чтобы принять участие в дискуссии (добавить собственные рецензию, или комментарий)